Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation Phase I Study of LNA-i-miR-221 for the Treatment of Refractory Multiple Myeloma and Advanced Solid Tumors

NCT04811898 is registered in ClinicalTrials.gov with Azienda Ospedaliera Universitaria Mater Domini, Catanzaro as lead sponsor.

NCT NCT04811898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04811898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation Phase I Study of LNA-i-miR-221 for the Treatment of Refractory Multiple Myeloma and Advanced Solid Tumors
Lead sponsor
Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
Phase
Phase 1
Overall status
Completed
Start date
January 14, 2019
Completion date
December 29, 2021
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, hepatocarcinoma, multiple myeloma, refractory